{"title": "SARS-CoV-2-Impfungen \u2013 Was muss der Nephrologe wissen?", "author": "Heine; Gunnar H; Becker; S\u00f6ren; Scheuer; Anja L; Schirmer; Stephan H", "url": null, "hostname": null, "description": "Impfstoffe Innerhalb von nur 15 Monaten nach Beginn der COVID-19-Pandemie stehen bereits mehrere SARS-CoV-2- Impfstoffe zum klinischen Einsatz bereit. W\u00e4hrend das Zielmolek\u00fcl aller pr\u00e4dominierenden Vakzine das Spike-Protein von SARS-CoV-2 ist, lassen sie sich anhand ihres Wirkprinzip in mRNA-basierte, Vektor-basierte und Protein-basierte Impfstoffe unterscheiden. Bedeutung f\u00fcr chronisch nierenkranke Menschen Das Aussprechen von Empfehlungen f\u00fcr chronisch nierenkranke Menschen ist aufgrund deren geringer Repr\u00e4sentation in den Zulassungsstudien erschwert \u2013 wie bei anderen Patienten mit schwerer Komorbidit\u00e4t. Aufgrund von ur\u00e4mischem Immundefekt und/oder medikament\u00f6ser Immunsuppression k\u00f6nnte die Effektivit\u00e4t der Impfung im Einzelfall relativ vermindert sein. Dennoch profitieren vermutlich gerade diese Patienten von einer Impfung, da sie ein erh\u00f6htes Risiko f\u00fcr einen schweren oder gar t\u00f6dlichen COVID-19-Verlauf aufweisen.", "sitename": "Thieme", "date": "2022-06-20", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Please use this identifier to cite or link to this item:\n[doi:10.22028/D291-36497] [Volltext verf\u00fcgbar? / Dokumentlieferung](http://www.redi-bw.de/links/unisb?sid=sulb%3Abib&issn=1439-4413&title=SARS-CoV-2-Impfungen+%E2%80%93+Was+muss+der+Nephrologe+wissen%3F&atitle=Deutsche+Medizinische+Wochenschrift)\n|Title:||SARS-CoV-2-Impfungen \u2013 Was muss der Nephrologe wissen?|\n|Other Titles:||SARS-CoV-2 vaccines - what the nephrologist should know|\n|Author(s):|\nSARS-CoV-2\nCOVID-19\nImmunsuppression\nVaccination\nSARS-CoV-2\nCOVID-19\nImmunosuppression\nOnly fifteen months after the beginning of the COVID-19 pandemic, several vaccines are already available for clinical use. While the spike protein of SARS-CoV-2 constitutes the main target of all predominant SARS-CoV-2 vaccines, they work by different mechanisms (mRNA-based vaccines vs. vector-based vaccines vs. protein-based vaccines). Though there are slight differences regarding the level of protection against mild COVID-19, all five vaccines that have been through phase 3 trials were nearly 100 % effective in preventing severe or fatal cases of COVID-19. The side effects were of short duration. Patients with chronic kidney disease (or other significant comorbidities) were largely excluded from Phase 3 trials, which makes definite recommendations concerning their vaccination difficult. The vaccine\u2019s effectiveness may be reduced in that population due to a uremic immune defect and/or immunosuppressive medication. However, these patients have an increased risk for severe or fatal COVID-19, so that they may particularly benefit from the vaccine.\n[urn:nbn:de:bsz:291--ds-364973](https://nbn-resolving.org/nbn:de:bsz:291--ds-364973) [hdl:20.500.11880/33141](http://hdl.handle.net/20.500.11880/33141) [http://dx.doi.org/10.22028/D291-36497](http://dx.doi.org/10.22028/D291-36497)\n0012-0472\nM - Innere Medizin\nM - P\u00e4diatrie\nM - Keiner Professur zugeordnet\n[SciDok - Der Wissenschaftsserver der Universit\u00e4t des Saarlandes](/handle/20.500.11880/3)\nFiles for this record:\nThere are no files associated with this item.\nItems in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.", "language": null, "image": null, "pagetype": null, "links": ["#content", "/", "#", "/help/SULB/policy.jsp", "/help/SULB/hinweise_zum_veroeffentlichen.jsp", "/help/SULB/embargo_info.jsp", "/help/SULB/zitieren.jsp", "/help/SULB/faq_scidok.jsp", "/help/SULB/hinweise_zum_melden.jsp", "/help/SULB/Nutzerhandbuch_en.pdf", "/help/SULB/faq_unibib.jsp", "http://www.sulb.uni-saarland.de/lernen/open-access/", "https://creativecommons.org/", "https://wb-web.de/material/medien/die-cc-lizenzen-im-uberblick-welche-lizenz-fur-welche-zwecke-1.html", "/help/SULB/kontakt.jsp", "/portale", "#", "?locale=de", "?locale=en", "#", "/mydspace", "/subscribe", "/profile", "/sulbprofile", "http://www.sulb.uni-saarland.de/", "http://www.uni-saarland.de/startseite.html", "/handle/20.500.11880/2", "/handle/20.500.11880/3", "https://dx.doi.org/10.22028/D291-36497", "http://www.redi-bw.de/links/unisb?sid=sulb%3Abib&issn=1439-4413&title=SARS-CoV-2-Impfungen+%E2%80%93+Was+muss+der+Nephrologe+wissen%3F&atitle=Deutsche+Medizinische+Wochenschrift", "/browse?type=author&value=Heine%2C+Gunnar+H.", "/browse?type=author&authority=1272", "/browse?type=author&value=Scheuer%2C+Anja+L.", "/browse?type=author&value=Schirmer%2C+Stephan+H.", "https://nbn-resolving.org/nbn:de:bsz:291--ds-364973", "http://hdl.handle.net/20.500.11880/33141", "http://dx.doi.org/10.22028/D291-36497", "/handle/20.500.11880/3", "/bibexport?handle=20.500.11880/33141&type=bib", "/handle/20.500.11880/33141/statistics", "https://dini.de/dienste-projekte/dini-zertifikat/", "http://www.sulb.uni-saarland.de/", "/help/SULB/kontakt.jsp", "/feedback", "https://www.uni-saarland.de/en/legal-notice.html", "https://www.uni-saarland.de/en/privacy.html"]}